SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Lum L) "

Sökning: WFRF:(Lum L)

  • Resultat 1-10 av 59
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  •  
3.
  • 2019
  • Tidskriftsartikel (refereegranskat)
  •  
4.
  •  
5.
  • Kvedaraite, E, et al. (författare)
  • Notch-dependent cooperativity between myeloid lineages promotes Langerhans cell histiocytosis pathology
  • 2022
  • Ingår i: Science immunology. - : American Association for the Advancement of Science (AAAS). - 2470-9468. ; 7:78, s. eadd3330-
  • Tidskriftsartikel (refereegranskat)abstract
    • Langerhans cell histiocytosis (LCH) is a potentially fatal neoplasm characterized by the aberrant differentiation of mononuclear phagocytes, driven by mitogen-activated protein kinase (MAPK) pathway activation. LCH cells may trigger destructive pathology yet remain in a precarious state finely balanced between apoptosis and survival, supported by a unique inflammatory milieu. The interactions that maintain this state are not well known and may offer targets for intervention. Here, we used single-cell RNA-seq and protein analysis to dissect LCH lesions, assessing LCH cell heterogeneity and comparing LCH cells with normal mononuclear phagocytes within lesions. We found LCH discriminatory signatures pointing to senescence and escape from tumor immune surveillance. We also uncovered two major lineages of LCH with DC2- and DC3/monocyte-like phenotypes and validated them in multiple pathological tissue sites by high-content imaging. Receptor-ligand analyses and lineage tracing in vitro revealed Notch-dependent cooperativity between DC2 and DC3/monocyte lineages during expression of the pathognomonic LCH program. Our results present a convergent dual origin model of LCH with MAPK pathway activation occurring before fate commitment to DC2 and DC3/monocyte lineages and Notch-dependent cooperativity between lineages driving the development of LCH cells.
  •  
6.
  •  
7.
  •  
8.
  • Matharu, M, et al. (författare)
  • Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe
  • 2017
  • Ingår i: Cephalalgia : an international journal of headache. - : SAGE Publications. - 1468-2982. ; 37:14, s. 1384-1397
  • Tidskriftsartikel (refereegranskat)abstract
    • To examine treatment utilization patterns and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine in routine clinical practice. Background Clinical trials support onabotulinumtoxinA for the prophylaxis of headache in patients with chronic migraine, but real-world data are limited. Design/methods A prospective, observational, post-authorization study in adult patients with chronic migraine treated with onabotulinumtoxinA. Data were collected at the first study injection and approximately every three months for ≤52 weeks for utilization and ≤64 weeks for safety data, and summarized using descriptive statistics. Results Eighty-five physicians (81% neurologists) at 58 practices in the United Kingdom, Germany, Spain, and Sweden participated and recruited 1160 patients (84.2% female, median age 46.6 years). At baseline, 85.8% of patients had physician diagnoses of chronic migraine/transformed migraine and reported an average of 11.3 (SD = 6.9) severe headache days per 28 days; 50.6% had previously used onabotulinumtoxinA for chronic migraine. A total of 4017 study treatments were observed. The median number of injection sites (n = 31) and total dose (155 U) were consistent across all treatment sessions, with a median 13.7 weeks observed between sessions. At least one treatment-related adverse event was reported by 291 patients (25.1%); the most frequently reported treatment-related adverse event was neck pain (4.4%). Most patients (74.4%) were satisfied/extremely satisfied with onabotulinumtoxinA treatment. Conclusions Patient demographics/characteristics are consistent with published data on the chronic migraine population. Utilization of onabotulinumtoxinA treatment for chronic migraine appears to be consistent with the Summary of Product Characteristics and published PREEMPT injection paradigm. No new safety signals were identified.
  •  
9.
  •  
10.
  • Thorburn, C. M., et al. (författare)
  • Association of PDCD1 genetic variation with risk and clinical manifestations of systemic lupus erythematosus in a multiethnic cohort
  • 2007
  • Ingår i: Genes and Immunity. - : Springer Science and Business Media LLC. - 1466-4879 .- 1476-5470. ; 8:4, s. 279-287
  • Tidskriftsartikel (refereegranskat)abstract
    • We evaluated the roles of five single-nucleotide polymorphisms (SNPs) within PDCD1, and haplotypes defined by these SNPs, for the development of systemic lupus erythematosus (SLE) and specific sub-phenotypes (nephritis, antiphospholipid antibody positive, arthritis and double-stranded DNA positive) within a multiethnic US cohort of 1036 patients. Family based analyses were performed using 844 simplex families from four ethnic groups (Caucasian, Asian, Hispanic and African American). Subjects were genotyped for five 'tag' SNPs (selected from 15) to provide complete genetic information in all main ethnic groups. We employed transmission disequilibrium testing to assess risk for SLE by allele or haplotype, and multiple logistic regression analysis of SLE cases to examine associations with specific sub-phenotypes. In family based analyses, a haplotype containing the PD1.3A allele was significantly associated with SLE susceptibility among Caucasian families (P=0.01). Among Hispanic families, two novel SNPs were associated with SLE risk (P=0.005 and 0.01). In multivariate logistic regression analyses, five haplotypes were associated with specific sub-phenotypes among the different ethnic groups. These results suggest that PDCD1 genetic variation influences the risk and expression of SLE and that these associations vary according to ethnic background.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 59
Typ av publikation
tidskriftsartikel (30)
konferensbidrag (29)
Typ av innehåll
refereegranskat (30)
övrigt vetenskapligt/konstnärligt (29)
Författare/redaktör
Kaneko, A (32)
Tarivonda, L (31)
Lum, JK (30)
Garruto, RM (30)
Dancause, KN (22)
Lee, G (19)
visa fler...
Sun, C. (19)
Pomer, A (19)
Olszowy, KM (19)
Regenvanu, R (19)
Chan, CW (18)
Silverman, H (18)
Taleo, G (16)
Weitz, CA (14)
Vilar, M (10)
Wilson, M (9)
Chan, C (9)
Abong, M (9)
Dehuff, C (9)
Soloway, LE (7)
Dreber Almenberg, An ... (6)
Li, M. (6)
Apicella, Coren L (6)
Campbell, Benjamin (6)
Lum, J. Koji (6)
Garcia, Justin R. (6)
Eisenberg, Dan T.A. (6)
Straube, A (5)
Pascual, J (5)
Lum, J (5)
Weitz, C (5)
Gowen, K (5)
Matharu, M (5)
Odom, D (5)
Lum, A (5)
Andrews, E (4)
Johannes, C (4)
Chen, JM (3)
Ginhoux, F. (3)
Gutierrez, L (3)
Remahl, IN (3)
Mann, H (3)
Khalilnezhad, A (3)
Larbi, A (3)
Howland, SW (3)
Zamore, Richard S. (3)
Lee, HK (3)
Davar, G (3)
Bennett, L (3)
Proctor, C (3)
visa färre...
Lärosäte
Karolinska Institutet (47)
Handelshögskolan i Stockholm (6)
Stockholms universitet (5)
Uppsala universitet (4)
Lunds universitet (4)
Göteborgs universitet (3)
visa fler...
Umeå universitet (2)
Linköpings universitet (2)
Sveriges Lantbruksuniversitet (2)
Högskolan i Halmstad (1)
Chalmers tekniska högskola (1)
Linnéuniversitetet (1)
visa färre...
Språk
Engelska (59)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (13)
Naturvetenskap (5)
Lantbruksvetenskap (2)
Samhällsvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy